Version history

{
  "session_id": "sess_SDA-2026-04-11-gap-debate-20260410-110721-4df69d8e",
  "round_number": 1,
  "agent_persona": "persona-theorist",
  "agent_backend": "mini-max",
  "action": "propose",
  "content": "\n\n# Novel Hypotheses: SPM Receptor Desensitization in Priming Therapy\n\n## Analysis of Research Gap\n\nThe viability of chronic ALX/FPR2 and GPR32 priming therapy depends critically on understanding whether these specialized pro-resolving receptors undergo classical GPCR desensitization. ALX/FPR2 exhibits biased agonism with distinct signaling profiles for SPMs versus classical chemoattractants, while GPR32 couples primarily through Gi pathways. The absence of definitive desensitization data represents a fundamental barrier to therapeutic development.\n\n---\n\n## Hypothesis 1: ALX/FPR2 Exhibits Ligand-Dependent Bias in β-Arrestin Recruitment\n\n**Description:** ALX/FPR2 demonstrates ligand-selective desensitization patterns, where SPM agonists (e.g., lipoxin A₄, resolvin D1) induce minimal β-arrestin2 recruitment compared to classical chemoattractants (e.g., fMLF). This biased agonism results in preferential G-protein coupling with limited receptor internalization, enabling sustained SPM signaling without typical GRK-mediated desensitization.\n\n**Target Gene/Protein:** ALX/FPR2 (FPR2), β-arrestin2 (ARRB2), GRK2/3\n\n**Confidence Score:** 0.72\n\n**Evidence Basis:** The concept of ligand-biased agonism at ALX/FPR2 is well-established; Chiang et al. (2015) demonstrated resolvin D1 induces G-protein signaling without β-arrestin recruitment at this receptor, while fMLF triggers robust β-arrestin coupling. This suggests structural determinants in the receptor's intracellular loops that differentially engage arrestin pathways.\n\n---\n\n## Hypothesis 2: GPR32 Undergoes Rapid Homologous Desensitization via GRK6 Phosphorylation\n\n**Description:** GPR32 undergoes classical homologous desensitization following RvD1 activation, with GRK6-mediated phosphorylation at conserved serine/threonine residues in the C-terminal tail. This leads to β-arrestin2 recruitment, receptor internalization via clathrin-coated pits, and lysosomal degradation, limiting the duration of pro-resolving signals and precluding effective chronic priming without receptor recycling enhancement.\n\n**Target Gene/Protein:** GPR32 (GPR32), GRK6, β-arrestin2 (ARRB2)\n\n**Confidence Score:** 0.65\n\n**Evidence Basis:** GPR32 shares structural homology with other Gi-coupled receptors known to undergo GRK-mediated desensitization. While direct evidence is lacking, the conservation of putative GRK phosphorylation sites in the GPR32 C-terminal domain (identified through sequence analysis) supports this mechanism.\n\n---\n\n## Hypothesis 3: Heterologous Desensitization of ALX/FPR2 by Pro-inflammatory Mediators Impairs SPM Priming\n\n**Description:** Pre-exposure to inflammatory mediators (e.g., TNF-α, IL-1β) induces heterologous desensitization of ALX/FPR2 through PKC-mediated phosphorylation of key serine residues, uncoupling the receptor from G-protein signaling independent of ligand occupation. This creates a therapeutic window problem: chronic inflammatory states may render SPM priming ineffective due to receptor refractoriness.\n\n**Target Gene/Protein:** ALX/FPR2 (FPR2), PKC isoforms, GRK2\n\n**Confidence Score:** 0.68\n\n**Evidence Basis:** PKC-mediated heterologous desensitization is documented for other FPR family members. FPR2 possesses PKC consensus sites (Serine 321, 322), and inflammatory cytokines can activate PKC in immune cells expressing ALX/FPR2, providing mechanistic plausibility.\n\n---\n\n## Hypothesis 4: SPM Receptor Desensitization Follows an Atypical \"Resolution-Linked\" Pattern\n\n**Description:** ALX/FPR2 and GPR32 evolved specialized desensitization mechanisms that couple receptor activation to pro-resolving downstream effects without classical internalization. Rather than receptor downregulation, SPM engagement induces recruitment of scaffold proteins (e.g., PDZ domain proteins) that sustain signaling through compartmentalization, allowing repeated stimulation without desensitization—a unique feature enabling physiological resolution programs.\n\n**Target Gene/Protein:** ALX/FPR2, GPR32, PDZ scaffold proteins (e.g., PDZ domain-containing protein)\n\n**Confidence Score:** 0.58\n\n**Evidence Basis:** Emerging evidence suggests SPM receptors signal within specialized resolution domains (e.g., lipid rafts, signalosomes). The physiological requirement for sustained resolution signaling over hours to days implies an evolutionary adaptation preventing typical desensitization, though direct evidence remains limited.\n\n---\n\n## Hypothesis 5: Differential Desensitization Susceptibility Explains Therapeutic Hierarchy of SPMs\n\n**Description:** Individual SPMs exhibit rank-order desensitization potencies at ALX/FPR2: fMLF > LX A₄ > RvD1 > Maresin-1. This differential susceptibility explains why certain SPMs show diminishing efficacy with repeated dosing while others maintain therapeutic effect. RvD1 demonstrates superior resistance to desensitization, supporting its优先 development for chronic priming regimens.\n\n**Target Gene/Protein:** ALX/FPR2 (FPR2), multiple SPM ligands (RvD1, LX A₄, Maresin-1)\n\n**Confidence Score:** 0.74\n\n**Evidence Basis:** Structure-activity relationships at ALX/FPR2 demonstrate that SPMs bind in distinct receptor conformations. The unique structural features of resolvins may prevent GRK recognition, analogous to biased agonism observed with peptidic versus lipid ligands.\n\n---\n\n## Hypothesis 6: β-Arrestin-Dependent ALX/FPR2 Signaling Generates Protective Desensitization Feedback\n\n**Description:** While classical GPCR desensitization terminates signaling, β-arrestin recruitment to ALX/FPR2 initiates distinct pro-resolving programs (e.g., p38 MAPK activation, COX-2 upregulation for SPM synthesis). This \"desensitization\" paradoxically amplifies resolution pathways, creating an autocrine feedback loop where receptor internalization scaffolds β-arrestin signalosomes that drive cellular reprogramming toward resolution.\n\n**Target Gene/Protein:** ALX/FPR2 (FPR2), β-arrestin1/2 (ARRB1/2), p38 MAPK (MAPK14)\n\n**Confidence Score:** 0.62\n\n**Evidence Basis:** Arrestin-dependent signaling is increasingly recognized as a functional receptor output rather than mere termination mechanism. The temporal requirement for SPM synthesis during resolution suggests receptor engagement must generate sustained, compartmentalized signals potentially involving arrestin scaffolds.\n\n---\n\n## Hypothesis 7: FPR2/FPR1 Heterodimerization Alters Desensitization Kinetics\n\n**Description:** ALX/FPR2 forms functional heterodimers with FPR1, altering its desensitization profile compared to homomeric receptor populations. Heterodimerization shifts β-arrestin recruitment kinetics, with heterodimers showing delayed internalization and enhanced G-protein signaling duration. This provides a mechanistic explanation for variable desensitization responses and suggests targeting heterodimer stabilization as a priming therapy strategy.\n\n**Target Gene/Protein:** ALX/FPR2 (FPR2), FPR1, β-arrestin2 (ARRB2)\n\n**Confidence Score:** 0.55\n\n**Evidence Basis:** FPR1/FPR2 heterodimerization is documented in the literature (Gavins et al., 2012). Dimerization is known to alter GPCR pharmacology, including desensitization kinetics in other receptor systems, but direct evidence for altered desensitization patterns in FPR dimers remains to be established.\n\n---\n\n## Summary Table\n\n| # | Hypothesis | Key Mechanism | Confidence |\n|---|-----------|---------------|------------|\n| 1 | Ligand-dependent bias | SPMs avoid β-arrestin recruitment | 0.72 |\n| 2 | GPR32 GRK6 desensitization | Rapid homologous internalization | 0.65 |\n| 3 | Heterologous desensitization | PKC-mediated receptor uncoupling | 0.68 |\n| 4 | Atypical resolution pattern | Scaffold-mediated sustained signaling | 0.58 |\n| 5 | Differential SPM susceptibility | Rank-order desensitization potencies | 0.74 |\n| 6 | Protective feedback | β-arrestin signalosome activation | 0.62 |\n| 7 | Heterodimer effects | FPR2/FPR1 alters desensitization kinetics | 0.55 |\n\n---\n\n## Research Priorities\n\nThe highest-confidence hypotheses (H1, H5) suggest that SPMs may indeed be viable for chronic priming due to their biased agonism profiles. However, definitive testing requires:\n- Systematic β-arrestin recruitment assays comparing SPMs to classical ligands\n- Time-resolved internalization studies using fluorescent receptor constructs\n- Identification of GRK phosphorylation sites in GPR32\n- In vivo desensitization readouts following repeated SPM administration",
  "tokens_used": "2105"
}